FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1037-1040 September 26, 2002 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Haber, D. Related Article by Kauff, N. D. Related Article by Rebbeck, T. R. PubMed Citation

To the Editor: Kauff et al. (May 23 issue)¹ present data suggesting that salpingo-oophorectomy provides protection against breast or gynecologic cancer in women with a BRCA1 or BRCA2 mutation. Although the follow-up period was relatively short and overall survival data are not yet available, the authors should be applauded for undertaking the only known prospective study of its kind. Since there are other options for reducing the risk of breast cancer,^2,3 we believe that the benefit of salpingo-oophorectomy should be evaluated separately in women with breast cancer and in those with gynecologic cancer. In a separate analysis shown in Table . . . [Full Text of this Article]

This article has been cited by other articles:

• Peshkin, B. N., Isaacs, C., Finch, C., Kent, S., Schwartz, M. D. (2003). Tamoxifen As Chemoprevention in BRCA1 and BRCA2 Mutation Carriers With Breast Cancer: A Pilot Survey of Physicians. JCO 21: 4322-4328 [Abstract] [Full Text]